IL241378B - Pharmaceutical preparations - Google Patents

Pharmaceutical preparations

Info

Publication number
IL241378B
IL241378B IL241378A IL24137815A IL241378B IL 241378 B IL241378 B IL 241378B IL 241378 A IL241378 A IL 241378A IL 24137815 A IL24137815 A IL 24137815A IL 241378 B IL241378 B IL 241378B
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
IL241378A
Other languages
English (en)
Hebrew (he)
Other versions
IL241378A0 (en
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL241378(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of IL241378A0 publication Critical patent/IL241378A0/en
Publication of IL241378B publication Critical patent/IL241378B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL241378A 2013-03-15 2015-09-09 Pharmaceutical preparations IL241378B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792440P 2013-03-15 2013-03-15
PCT/US2014/029421 WO2014144842A2 (en) 2013-03-15 2014-03-14 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
IL241378A0 IL241378A0 (en) 2015-11-30
IL241378B true IL241378B (en) 2022-01-01

Family

ID=50732290

Family Applications (2)

Application Number Title Priority Date Filing Date
IL241378A IL241378B (en) 2013-03-15 2015-09-09 Pharmaceutical preparations
IL288961A IL288961A (en) 2013-03-15 2021-12-13 Pharmaceutical preparations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL288961A IL288961A (en) 2013-03-15 2021-12-13 Pharmaceutical preparations

Country Status (18)

Country Link
US (2) US11129869B2 (enExample)
EP (2) EP2970389B1 (enExample)
JP (4) JP6538025B2 (enExample)
KR (1) KR102378943B1 (enExample)
CN (3) CN115957297A (enExample)
AU (5) AU2014228460B2 (enExample)
BR (1) BR112015023409B1 (enExample)
CA (2) CA3209602A1 (enExample)
DK (1) DK2970389T3 (enExample)
ES (1) ES2825076T3 (enExample)
FR (1) FR21C1059I2 (enExample)
IL (2) IL241378B (enExample)
NL (1) NL301149I2 (enExample)
NO (1) NO2021051I1 (enExample)
PL (1) PL2970389T3 (enExample)
PT (1) PT2970389T (enExample)
RU (1) RU2690377C2 (enExample)
WO (1) WO2014144842A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
US10196425B2 (en) * 2013-03-15 2019-02-05 Rhythm Pharmaceuticals, Inc. Peptide compositions
EP2970389B1 (en) * 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
HK1216152A1 (zh) * 2013-04-11 2016-10-21 Vanderbilt University 複合體
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
PT3356386T (pt) 2015-09-30 2024-05-17 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados à via do receptor da melanocortina-4
JP6701572B2 (ja) * 2016-07-05 2020-05-27 株式会社リコー インク、収容容器、画像形成方法及び画像形成装置
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
MA49883A (fr) 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
UY37969A (es) * 2017-11-15 2019-06-28 Rhythm Pharmaceuticals Inc Formulaciones de peptidos de liberación sostenida
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
KR102087634B1 (ko) * 2018-10-11 2020-03-11 (주)바이텍 항비만용 조성물
KR20210116505A (ko) * 2019-01-04 2021-09-27 키네타 크로닉 페인, 엘엘씨 코노톡신 펩티드 유사체 및 통증 및 염증성 병태의 치료를 위한 용도
AU2021208601B2 (en) 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN111718408A (zh) * 2020-07-06 2020-09-29 成都圣诺生物制药有限公司 一种Setmelanotide的制备方法
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
WO2023080712A1 (ko) * 2021-11-05 2023-05-11 ㈜아이엠디팜 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물
WO2023247999A1 (en) * 2022-06-24 2023-12-28 Mainline Biosciences (Shanghai) Co., Ltd. Peptidic pain modulators and methods for producing and using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU6785094A (en) 1993-05-07 1994-12-12 Sequus Pharmaceuticals, Inc. Subcutaneous liposome delivery method
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
WO2003006620A2 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
JP2005504715A (ja) * 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
AU2004251616A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
US8349797B2 (en) 2005-07-08 2013-01-08 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
JP4734411B2 (ja) * 2005-07-08 2011-07-27 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンド
US8563000B2 (en) * 2007-05-25 2013-10-22 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
TW200848424A (en) 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
CN101980717A (zh) 2007-11-05 2011-02-23 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
US20090305960A1 (en) * 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
UA104866C2 (uk) * 2008-06-25 2014-03-25 Ендо Фармас'Ютікалз Солюшнз Інк. Імплантат октреотиду, який містить вивільняючу речовину
CN101439182B (zh) * 2008-12-18 2012-02-01 北京大学 一种生长抑素受体介导的肿瘤靶向药物组合物
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
IN2012DN01493A (enExample) 2009-08-05 2015-06-05 Ipsen Pharma Sas
CN102686601A (zh) 2009-11-16 2012-09-19 益普生制药股份有限公司 合成Ac-Arg-环(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2的方法
EP2501225B1 (en) 2009-11-16 2017-11-01 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
JP6072020B2 (ja) 2011-06-14 2017-02-01 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． メラノコルチンリセプターリガンドを有効成分として含有する持続放出性組成物
JP2013046596A (ja) * 2011-08-29 2013-03-07 Alpha-Nano-Medica Co Ltd 新規な複合体、それを含有する医薬及び癌の治療方法
WO2013033838A1 (en) * 2011-09-09 2013-03-14 Pharmagap Inc. Liposomal formulations of cationic peptides and uses thereof
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
EP2970389B1 (en) * 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
US10196425B2 (en) * 2013-03-15 2019-02-05 Rhythm Pharmaceuticals, Inc. Peptide compositions

Also Published As

Publication number Publication date
JP6538025B2 (ja) 2019-07-03
BR112015023409A8 (pt) 2019-12-03
ES2825076T3 (es) 2021-05-14
US11129869B2 (en) 2021-09-28
DK2970389T3 (da) 2020-10-26
FR21C1059I1 (fr) 2022-01-21
CA2906782A1 (en) 2014-09-18
JP2022065117A (ja) 2022-04-26
KR20160020405A (ko) 2016-02-23
CN105518021A (zh) 2016-04-20
HK1220702A1 (en) 2017-05-12
IL288961A (en) 2022-02-01
JP2019189619A (ja) 2019-10-31
US12285460B2 (en) 2025-04-29
JP2025004067A (ja) 2025-01-14
EP3778623A1 (en) 2021-02-17
KR102378943B1 (ko) 2022-03-25
AU2014228460B2 (en) 2018-11-01
BR112015023409B1 (pt) 2023-11-28
WO2014144842A2 (en) 2014-09-18
PL2970389T3 (pl) 2021-03-08
PT2970389T (pt) 2020-10-21
BR112015023409A2 (pt) 2017-07-18
AU2014228460A1 (en) 2015-10-01
RU2690377C2 (ru) 2019-06-03
RU2015143965A (ru) 2017-04-24
AU2023204625A1 (en) 2023-08-03
AU2021202699A1 (en) 2021-05-27
CA2906782C (en) 2023-10-03
CN115957297A (zh) 2023-04-14
FR21C1059I2 (fr) 2022-12-02
EP2970389B1 (en) 2020-08-19
JP2016516062A (ja) 2016-06-02
WO2014144842A3 (en) 2015-04-09
US20160022764A1 (en) 2016-01-28
US20220160818A1 (en) 2022-05-26
EP2970389A2 (en) 2016-01-20
AU2025213562A1 (en) 2025-08-21
CA3209602A1 (en) 2014-09-18
NO2021051I1 (no) 2024-08-05
NL301149I2 (nl) 2022-11-24
CN115957296A (zh) 2023-04-14
AU2019200101B2 (en) 2021-02-04
RU2019116003A (ru) 2019-07-17
AU2019200101A1 (en) 2019-01-31
NL301149I1 (enExample) 2021-12-08
IL241378A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
PL2943181T3 (pl) Kompozycje farmaceutyczne
SMT201900684T1 (it) Composizione farmaceutica combinata
GB201304662D0 (en) Compositions
ZA201408333B (en) Pharmaceutical compositions
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
GB201608461D0 (en) Compositions
IL241254A0 (en) Pharmaceutical preparations containing everolimus
EP3003324A4 (en) Pharmaceutical compositions
SG11201601477VA (en) Pharmaceutical composition
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
IL242704B (en) Pharmacy preparation
GB201320962D0 (en) Compositions
ZA201506637B (en) Micronized pharmaceutical compositions
ZA201601645B (en) Bendamustine pharmaceutical compositions
HUP1300496A2 (hu) Stabil kombinációs gyógyszerkészítmény
IL244365A0 (en) pharmaceutical preparation
SG11201509114TA (en) Pharmaceutical compositions
GB201304699D0 (en) Pharmaceutical compositions
GB201320959D0 (en) Compositions
GB201321497D0 (en) Pharmaceutical compositions
GB201312851D0 (en) Pharmaceutical compositions
GB201304625D0 (en) New pharmaceutical composition
GB201316662D0 (en) Pharmaceutical Combination
GB201312224D0 (en) Compositions